U.S. market Closed. Opens in 17 hours 13 minutes

TFX | Teleflex Incorporated Stock Overview

(Stock Exchange: NYSE)
Day's Range 245.36 - 248.68
52 Week Range 177.63 - 257.85
Beta 1.17
Implied Volatility 32.32%
IV Rank 36.79%
Day's Volume 279,318
Average Volume 420,512
Shares Outstanding 47,117,500
Market Cap 11,593,260,875
Sector Healthcare
Industry Medical - Instruments & Supplies
IPO Date 1980-03-17
Valuation
Profitability
Growth
Health
P/E Ratio 44.02
Forward P/E Ratio N/A
EPS 5.59
1YR Price Target N/A
Dividend Yield 0.55%
Dividend Per Share 1.36
Dividend ExDate N/A
Dividend PayDate N/A
Employees 14,500
Country USA
Website TFX
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.
TFX's peers: ALC, ATR, BAX, BDX, BLFS, COO, CTLT, HAE, HOLX, ISRG, MMSI, NVST, RGEN, RMD, STVN, WST, ICUI, ANGO, WRBY, XRAY, EMBC, BLCO
*Chart delayed
Analyzing fundamentals for TFX we got that it has average fundamentals where Valuation is considered to be slightly undervalued, Profitability is unacceptably poor, Growth is very good and Health is passable. For more detailed analysis please see TFX Fundamentals page.

Watching at TFX technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on TFX Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙